Inhalation Sciences receives green light from the US FDA to start the experimental phase of FDA BAA dissolution research project
(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project, ISAB today announces that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company’s facilities in Sweden.The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB’s DissolvIt technology by comparing drug formulations, aimed for administration via inhalation, with